Potassium-Sparing Diuretics Market - Top Companies and Manufacturers

  • Report ID: 3292
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Companies Dominating the Potassium-Sparing Diuretics Landscape

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Merck Sharp & Dohme Corp.
    • Accord Healthcare
    • Amneal Pharmaceuticals LLC
    • Centaur Pharmaceuticals Pvt. Ltd.
    • Validus Pharmaceuticals LLC
    • Teva Pharmaceutical Industries Ltd.
    • CMP Pharma
    • Boehringer Ingelheim GmbH
    • Bayer AG

Browse Key Market Insights with Data Illustration:

In the News

  • A new FDA approval for Merck & Co., Inc., VERQUVO® (vericiguat) has been announced. heart failure (HF) hospitalization risk reduction with VERQUVO in adults with symptomatic chronic heart failure and a low ejection fraction (45%) after heart failure hospitalization or need for intravenous (IV) diuretics in adults.

  • In a joint announcement today, Boehringer Ingelheim GmbH and Eli Lilly and Company announced that Jadix® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration for the reduction of cardiovascular death and hospitalization associated with heart failure in adults with heart failure with reduced ejection fractions (HFrEF).


Author Credits:  Radhika Pawar


  • Report ID: 3292
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of potassium-sparing diuretics is estimated at USD 122.87 million.

The potassium-sparing diuretics market size was valued at USD 112.04 million in 2024 and is likely to cross USD 236.06 million by 2037, registering more than 5.9% CAGR during the forecast period i.e., between 2025-2037. The growing prevalence of chronic diseases, such as hypertension and kidney diseases, and the increasing demand for better treatments will boost the market growth.

North America industry is poised to dominate majority revenue share of 39% by 2037, propelled by increasing prevalence of cardiovascular diseases and the increasing demand for safe and effective medicines.

The major players in the market are Pfizer Inc., Merck Sharp & Dohme Corp., Accord Healthcare, Amneal Pharmaceuticals LLC, Centaur Pharmaceuticals Pvt. Ltd., Validus Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., CMP Pharma, Boehringer Ingelheim GmbH, Bayer AG
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample